In recent trading session, Cogent Biosciences Inc. (NASDAQ:COGT) saw 1.48 million shares changing hands at last check today with its beta currently measuring 1.72. Company’s recent per share price level of $10.89 trading at $0.02 or 0.18% at last check today assigns it a market valuation of $729.59M. That most recent trading price of COGT’s stock is at a discount of -65.93% from its 52-week high price of $18.07 and is indicating a premium of 65.2% from its 52-week low price of $3.79. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.69 million shares which gives us an average trading volume of 846.05K if we extend that period to 3-months.
For Cogent Biosciences Inc. (COGT), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.30. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.51 in the current quarter.
Cogent Biosciences Inc. (NASDAQ:COGT) trade information
Upright in the green today for gaining 0.18%, in the last five days COGT remained trading in the red while hitting it’s week-highest on Friday, 11/18/22 when the stock touched $10.89 price level, adding 6.36% to its value on the day. Cogent Biosciences Inc.’s shares saw a change of 26.69% in year-to-date performance and have moved -2.25% in past 5-day. Cogent Biosciences Inc. (NASDAQ:COGT) showed a performance of -19.30% in past 30-days. Number of shares sold short was 4.68 million shares which calculate 7.96 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $21.17 to the stock, which implies a rise of 48.56% to its recent value today. Analysts have been projecting $18.00 as a low price target for the stock while placing it at a high target of $28.00. It follows that stock’s current price would drop -157.12% in reaching the projected high whereas dropping to the targeted low would mean a loss of -65.29% for stock’s current value.
Cogent Biosciences Inc. (COGT) estimates and forecasts
Statistics highlight that Cogent Biosciences Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 128.84% of value to its shares in past 6 months, showing an annual growth rate of -23.53% while that of industry is 4.40. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 15.00% in the current quarter and calculating 29.40% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.40% during past 5 years.
Cogent Biosciences Inc. is more likely to be releasing its next quarterly report on November 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Cogent Biosciences Inc. (NASDAQ:COGT)’s Major holders
Insiders are in possession of 0.01% of company’s total shares while institution are holding 110.58 percent of that, with stock having share float percentage of 110.59%. Investors also watch the number of corporate investors in a company very closely, which is 110.58% institutions for Cogent Biosciences Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at COGT for having 4.6 million shares of worth $50.21 million. And as of Sep 29, 2022, it was holding 6.99% of the company’s outstanding shares.
The second largest institutional holder is Commodore Capital, LP, which was holding about 4.32 million shares on Sep 29, 2022. The number of shares represents firm’s hold over 6.57% of outstanding shares, having a total worth of $47.2 million.
On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 5.09 million shares of worth $55.66 million or 7.75% of the total outstanding shares. The later fund manager was in possession of 2.46 million shares on Oct 30, 2022, making its stake of worth around $26.93 million in the company or a holder of 3.75% of company’s stock.